Clinical Sessions for Recertification: Oncology (Cert # L209334)

ACPE Numbers:

Pre-Sale Date: 11/18/2020
Content Release Date: 12/16/2020
Expiration Date: 12/14/2021
Activity Type: Application-based
CE Credits: 4.0 hours
Activity Fee: $150 (ASHP member); $250 (non-member)

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as a providers of continuing pharmacy education.

Target Audience

These recertification activities are intended for board-certified pharmacists seeking to update their knowledge and skills in:

  • Oncology Supportive Care

Activity Overview

The Clinical Sessions Package is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). Using a case-based approach, the activities provide high-level, interactive discussions on contemporary and emerging issues in oncology.

The Oncology Clinical Sessions Recertification Package consists of 2 activities (see table below) and provides up to 4.0 hours of continuing pharmacy education and/or recertification credit.  

These activities are part of the ASHP and ACCP professional development program for BCOP recertification approved by the BPS.

Recertification Credit*

Board-certified pharmacists are eligible to receive up to 4.0 hours of recertification credit for completing this package. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Recertification credit is earned in the calendar year in which you pass the recertification assessment.

Learning Module

ACPE Number

Credit Hours


*Assessment Pass Point

Oncology Supportive Care: Navigating the Expanding Realm of Oral Small Molecule Inhibitors





Why Am I Only Offering Oncology Pain Patients Opioids? Is There Anything Else, Anything at All?





Learning Objectives

ACPE Number: 0217-9999-20-123-H01-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Describe the mechanism of action of tyrosine kinase inhibitors and multi-kinase inhibitors and how the differences contribute to their respective toxicity profile.
  • Evaluate the current monitoring parameters for FDA-approved small molecule inhibitors and recognize areas of ambiguity.
  • Design a customized treatment plan for a patient presenting with a small molecule inhibitor-related adverse event.
  • Recommend effective approaches for monitoring patients on small molecule inhibitors to improve patient outcomes.

ACPE Number: 0217-9999-20-124-H08-P

Learning Objectives

At the conclusion of this application-based educational activity, participants should be able to do the following:

  • Identify oncology patients which would benefit the most from additional non-opioid pain management options.
  • For a given patient, describe the possible mechanism of pain and choose an appropriate therapeutic option based on available evidence for management.
  • Given a patient case, identify which IT pump therapy would be most beneficial to the patient’s oncologic pain management regimen.
  • For a given patient, evaluate whether he/she would have an indication for interventional therapies.


Planners, Presenters, and Reviewers

Full Faculty Bios 

Pharmacy Pain Management Clinical Specialist
Kaweah Delta Health Care District
Visalia, California

Assistant Professor of Pharmacy Practice/Hematology-Oncology Clinical Pharmacist
Palm Beach Atlantic University and Cleveland Clinic Florida
West Palm Beach, Florida

Acute Pain Clinical Pharmacist
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota

Assistant Professor of Pharmacy & Hematology/Oncology Clinical Pharmacist
Mayo Clinic College of Medicine and the University of Minnesota Medical Center
Minneapolis, Minnesota

Clinical Assistant Professor
The University of Iowa Carver School of Medicine
Iowa City, Iowa

Clinical Oncology Pharmacist
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah

Associate Professor of Pharmacy PracticeDuquesne University School of Pharmacy
Clinical Pharmacy Specialist
UPMC Passavant Hospital
Pittsburgh, Pennsylvania

Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Associate Member
Department of Individualized Cancer Management
H. Lee Moffitt Cancer Center
Associate Professor, Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, Florida

Donald Moore, Pharm.D., BCPS, BCOP, DPLA
Kelly K. Nystrom, Pharm.D., BCOP
Amanda N. Seddon, Pharm.D., BCPS, BCOP

Divine Chi, Pharm.D, BCPS, BCOP
Merta Cushing, Pharm.D., BCOP
Marjan Forouzan, Pharm.D., BCOP
Tom Geiser, Pharm.D. , BCOP
Anne Holbrook, Pharm.D., BCOP
I-Kuan Hsu, Pharm.D., BCPS, BCOP
Caren Hughes, Pharm.D., M.B.A., BCOP
David Hughes, Pharm.D., BCOP
Anna Jan, Pharm.D., BCOP
Lisa Janssen Carlson, Pharm.D., BCOP
Shraddha Kansagra, Pharm.D., BCOP
Sidney Keisner, Pharm.D., BCOP
Claire Mach, Pharm.D., BCOP
Michael Masterson, R.Ph., BCOP
Stephanie Matta, Pharm.D., BCOP
Terry Pak, Pharm.D., BCOP
Gloria Porcelli, R.Ph., BCOP
Anu Pradhan, Ph.D., R.Ph., BCOP
Brendan Rasor, Pharm.D., BCOP
Forrest Ridgway, Pharm.D., BCOP
Joslyn Rudoni, Pharm.D., BCOP
Samantha Shi, Pharm.D., BCOP
Sunao Slayton, Pharm.D. BCOP
Matthew Stankowicz, Pharm.D., BCOP
Caroline Townley, Pharm.D., BCOP
Vivian Tsang, Pharm.D., BCOP, BCPS
Long Vo, Pharm.D., BCPS, BCOP
Chen Xu, Ph.D., M.S., BCOP
Barbara Yim, Pharm.D., BCOP
Lauren Zion, Pharm.D., BCOP, BCPS


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP and ACCP education activities are qualified and selected by ASHP and ACCP and required to disclose any relevant financial relationships with commercial interests. ASHP and ACCP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

All other planners, presenters, reviewers, ASHP and ACCP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of audio/video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.


These activities were developed by ACCP and ASHP.